difficult. A blood pool subtraction may be performed, but this is not entirely satisfactory (Jones et al., 1982) . A secondary antibody, i.e. one raised against the radiolabelled antibody (primary antibody), might bind to its antigen in the circulation and facilitate its clearance. If free secondary antibody were to be used, rapid clearance would only result if large lattice complexes were to form from the two antibodies present in a ratio close to equivalence. However, if the secondary antibody were to be entrapped in liposomes, in such a way that it was still able to bind to primary antibody, the resulting complexes would be cleared rapidly to liver and spleen (Fig. lb) . Since liposomes do not normally penetrate epithelia other than in the reticuloendothelial system, it is unlikely that LESA would affect the tumour-bound primary antibody. We have tested this approach in both animal and human situations. Secondary antibody to goat anti-CEA, used for the radio-immunodetection of colorectal carcinonoma, was raised in horse, partially purified to an immunoglobulin-G fraction, and entrapped in liposomes as previously described (Barratt et al., 1983) . Carefully timed sonication allowed 50% of the added antibody to be incorporated in liposomes, and of this, 10% was available to bind to the antigen, anti-CEA.
LESA was tested initially in experimental animals, particularly in mice, since 'nude' immuno-deprived mice bearing CEA-secreting xenografts were available. In normal mice the effect of following intravenous injections of 12SI-labelled anti-CEA with LESA 24h later was to decrease the blood concentrations of anti-CEA to one-third of those found in control animals that did not receive LESA (Barratt et al., 1983) . LESA also caused anti-CEA to be taken in to the liver and spleen in the early part of the experiment and to be later released. In tumour-bearing animals similar results were obtained, and in addition it was observed that LESA administration did not significantly alter the uptake of anti-CEA by the tumour in the first 6 h after treatment. In two different xenograft systems LESA was able to improve the tumour/blood ratios of anti-CEA.
In these experiments, the ratio of secondary antibody to primary antibody was high, 100 : I to lo00 : 1. We investigated the optimal ratio of the two antibodies, with the secondary antibody present either as LESA or as free antibody, in a mouse system. For LESA, maximum clearance was achieved with a secondarylprimary ratio of 60 : I , and with free antibody the ratio was 10 : I. This is to be expected, as not all LESA is available to bind antigen. At their optimal concentrations, free and entrapped secondary antibody promote identical tumour/blood ratios of anti-CEA, and similar distributions to the liver and spleen (K. A. Chester, R. H. J. Bogent, G. M. Barratt, B. E. Ryman & K. D. Bagshawe, unpublished work). However, LESA was still thought to be advantageous, because it avoided the problems of circulating immune complexes. After we had tested LESA for any signs of producing serum sickness in rabbits, a short clinical trial was begun.
Five patients with elevated serum CEA believed to be due to metastatic gastro-intestinal cancer were given I 3 1 Ilabelled anti-CEA, followed 24 h later by sterile liposomes containing horse-anti-goat secondary antibody, prepared as for the animal experiments. The liposomes contained 3-32mg of protein entrapped in 4C300mg of lipids. The antibody ratios were 30 : 1 to 300 : 1. yRay scans were made before administration of liposomes and 2 4 8 h later, and serum samples were taken at similar intervals.
In four of the five patients treated, the rate of anti-CEA clearance was accelerated after LESA had been given. This was related to the dose of LESA given (Begent et al., 1982) . In one patient, an area of CEA retention behind the bladder was identified, and confirmed as metastatic cancer by computerized tomography. In another patient an area of retention was observed over the para-aortic lymph nodes. This is illustrated by Fig. 2 . Regions of interest were defined on the y-camera image over the heart, lungs, liver and paraaortic nodes. Counts in these areas were measured on scans made at various times before and after LESA, and clearance of anti-CEA from these regions was plotted (Fig. 2) . The antibody clears rapidly from heart and lungs after LESA, but accumulates temporarily in the liver. This is similar to observations made in animal models. Anti-CEA retention in the para-aortic region is clearly shown. The presence of a secondary deposit here was again confirmed by computerized tomography. In a patient who did not have tumour in this area, a similar treatment of y-camera data did not reveal anti-CEA retention (Begent et al., 1982) . LESA has also improved discrimination in scans performed with a monoclonal antibody to colorectal cancer. In this case the secondary antibody incorporated in the liposomes was rabbit anti-mouse. Thus we believe that we have shown that in principle clearance by secondary antibody can aid discrimination in radio-immunolocalization, and that liposomal entrapment of secondary antibody may have advantages over free secondary antibody. The latter is easier to prepare in a sterile and pyrogenfree manner, and is less wasteful of antibody, since all is available to bind antigen. LESA, however, has the advantage that large, rapidly cleared, complexes will be formed irrespective of antibody ratios, and possible toxic effects of circulating immune complexes will be overcome. The problems of antibody availability and of possible antibody leakage may be overcome by using covalently coupled antibody, since many methods of achieving this are now available.
As well as use in detection, secondary-antibody clearance may have a role to play in the antibody-mediated therapy of tumours. These might be selectively irradiated by labelled anti-tumour antibodies of high specific radioactivity. Antibodies might also be coupled to an active antineoplastic drug or toxin. Obviously, it is important to lessen normal tissue doses during such a therapy. Build-up in the tumour area might be achieved by giving a number of doses of toxic antibody, interspersed by secondary antibody to clear the circulation. In a pilot experiment LESA was effective in such a procedure. Free secondary antibody might present a problem here, because a small proportion of the injected material seems to persist in the circulation, possibly as immune complexes, and this decreases the efficiency of a second dose. Of course, the effect on the liver of a rapid uptake of toxic agent during clearance of liposomes will have to be carefully assessed.
In conclusion, we have shown a possible use of liposomes in medicine which exploits their natural clearance to the liver and spleen, which, notwithstanding the successful results with liposome targeting, must be the most profitable line of research for the future.
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A recombinant plasmid encoding rat preproinsulin I was encapsulated in large liposomes and injected intravenously into rats. Glycaemia and blood, splenic and hepatic insulin were assayed from 6h after inoculation. Control animals received (i) empty liposomes, (ii) liposomes carrying the Escherichia coli pBR 322 plasmid, (iii) the free rat insulin I gene, or (iv) no injection. All controls showed unchanged glucose and insulin concentrations. At 6 h after inoculation the treated rats had 72fSmg of glucose/lOoml of blood, VOl. 12 compared with 107* 8pnits/ml for controls). Spleen and liver values were 242k22 and 204+20punits/g of tissue respectively (1 12 20 and 87 f 1 Spunitslg in controls). The kinetics and extent of uptake of liposomes by spleen and liver were studied by external y-camera imaging after injection of 1 I In-labelled liposomes. The results paralleled insulin synthesis in the two organs.
The insulin gene was localized in liver cells after injection of liposomes containing the plasmid encoding the gene. Livers were processed 4h after inoculation for isolation of hepatocytes, Kupffer cells and endothelial cells. DNA was purified and exogenous DNA detected by Southern blotting. Kupffer cells were the primary target for gene incor-
